arrow
J

Jing Kan

Nanjing Medical University
H指数:23
被引数:3,824

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

One vs twelve month aspirin after percutaneous coronary intervention for acute myocardial infarction: individual patient-data analysis of TARGET-FIRST and ULTIMATE-DAPT trials

急性心肌梗死经皮冠状动脉介入治疗后服用阿司匹林1个月与12个月的比较:TARGET-FIRST和ULTIMATE-DAPT试验的个体患者数据分析

2026-08-290
OAAI
Real-World Predictor Factors and Clinical Outcomes in Patients With Major Depressive Disorder Undergoing Percutaneous Coronary Intervention: Rationale and Study Protocol for the PCI CODE Study

真实世界预测因子与接受经皮冠状动脉介入治疗的抑郁症患者临床结局:PCI CODE研究的原理和方案

2025-12-010
PRE
Intravascular ultrasound-guided percutaneous coronary intervention in acute coronary syndrome stratified by the TVF-ACS risk score: the IVUS-ACS trial
2025-11-010
OA
Intravascular imaging-guided versus angiography-guided percutaneous coronary intervention in patients with diabetes mellitus: Rationale and design of an international, multicenter, randomized IVI-DIABETES trial

血管内影像引导与血管造影引导经皮冠状动脉介入治疗在糖尿病 mellitus 患者中的应用:一项国际、多中心、随机 IVI-DIABETES 试验的背景与设计

2025-05-010
PRE
PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study
2024-11-013
PRE
Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT) a randomised, placebo-controlled, double-blind clinical trial

替格瑞洛单药与替格瑞洛加阿司匹林在急性冠脉综合征患者经皮冠状动脉介入治疗后第1个月至第12个月的比较 (ultimite-dapt) 一项随机、安慰剂对照、双盲临床试验

LANCET
IF88.5
2024-05-0134
PRE
A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial
2023-10-015
PRE
Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial

通过REVEAL风险评分分层肺动脉去神经术对肺动脉高压的治疗效果: 来自padn-cfda试验的结果

2023-08-015
PRE
Pulmonary Artery Denervation for Pulmonary Arterial Hypertension A Sham-Controlled Randomized PADN-CFDA Trial

肺动脉去神经术治疗肺动脉高压的假对照随机padn-cfda试验

2022-12-0128
OAAI
Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms
2022-06-173
OAAI